Portfolio of ARV Products for HIV Released in India

A comprehensive portfolio of 18 antiretroviral (ARV) products has been released in India for the treatment of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). India has the world's third largest population of people with HIV/AIDS, with approximately 2.4 million people living with the disease, of which fewer than 20% have access to treatment.

Mylan Pharmaceuticals Private Ltd., a subsidiary of Mylan Inc. (Canonsburg, PA, USA) a generic and specialty pharmaceutical company, launched its portfolio of AVR products in India for treatment of HIV/AIDS.

Heather Bresch, CEO Mylan, commented: "We see significant growth potential in India, the world's second largest pharmaceutical market by volume, and look forward to continuing to expand our operations in India in additional therapeutic categories."

Mylan Laboratories Limited (formerly Matrix Laboratories), provides supplies of ARV active pharmaceutical ingredients (API) to generic drug makers. In 2007, the company began offering finished dosage forms and launched a line of pediatric ARVs.

Mylan's Nashik, India facility, which produces the company's finished-dosage-form ARVs for markets around the world including India, has been subject to Good Manufacturing Practices (GMP) inspections by several leading regulatory authorities, including the US Food and Drug Administration (FDA; Silver Springs, MD, USA) and the World Health Organization (WHO; Geneva, Switzerland).

Mylan also has introduced a number of ARV innovations, such as single blister combo packs, which provide a reduced pill burden and once-a-day dosage. Mylan also developed three FDA/WHO-approved heat-stable ARV products, which can be distributed and used in warm climates where refrigeration infrastructure is not widely available.

Related Links:
Mylan Inc.
US Food and Drug Administration
World Health Organization